EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence

Margaux Tual, Angélique Bellemare-Pelletier, Susan Moore, Delphine Guipouy, Negar Farzam-Kia, Leila Jafarzadeh, Jordan Quenneville, Benoit Barrette, Marc K Saba-El-Leil, Jean-Sebastien Delisle, Etienne Gagnon

Journal for ImmunoTherapy of Cancer · 2025-04 · 13 (4) · e011829

DOI: 10.1136/jitc-2025-011829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.04.2025. Verfasst von Margaux Tual und 10 weiteren Autor:innen. Beteiligte Einrichtung: Département de microbiologie, Université de Montréal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Institute of Infection and Immunity, Stem Cell Network, Leukemia and Lymphoma Society of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor T cell (CAR-T)-based immunotherapies have reshaped the therapeutic landscape of cancer treatment, in particular for patients afflicted with leukemia. However, defects in CAR behaviors and clinical complications have hindered their widespread application across diverse cancer types. Chief among these defects is high tonic signaling, absent in native activating immune receptors, which accelerates T cell exhaustion and undermines treatment efficacy. We hypothesized that these limitations arise because current CAR architectures fail to replicate the modular design of native activating immune receptors, which integrate distinct receptor and signaling modules. This modular assembly is crucial for maintaining proper receptor regulation and function.

Methods

Therefore, we set forth to develop a modular chimeric antigen receptor leveraging the same assembly principles found in native activating immune receptors to reestablish the intrinsic safeguards in receptor expression and signaling.

Results

The resulting Modular Actuation Receptor Complex (MARC) displayed surface expression levels akin to its native immune receptor counterpart, the NK cell receptor KIR2DS3, while eliminating tonic signaling. In a clinically relevant mouse leukemia model, MARC-T cells exhibited remarkable long-term persistence and a less exhausted phenotype compared with conventional CAR-T cells.

Conclusions

With its modular architecture, the MARC offers unparalleled opportunities for optimization and broad applicability across different cell types, paving the way for transformative advancements in cell-based therapies. This innovation holds immense promise as a next-generation therapeutic tool in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesImmunotherapyAnimalsMiceHumansT-Cell Exhaustion

Stichwörter der Autor:innen

Antigen receptor designChimeric antigen receptor - CARImmunotherapyLeukemiaT cell

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Département de microbiologie, Université de Montréal, Montreal, Quebec, Canada.
  • Université de Montréal Institut de Recherche en Immunologie et en Cancérologie, Montréal, Québec, Canada.
  • Modulari-T biosciences, Montréal, Quebec, Canada.
  • Médicine, Maisonneuve-Rosemont Hospital Research Centre, Montréal, Québec, Canada.
  • Département de médecine, Université de Montréal, Montréal, Québec, Canada.
  • Département de biologie et pathologie cellulaire, Université de Montréal, Montreal, Quebec, Canada.

Förderung

  • Institute of Infection and Immunity
  • Stem Cell Network
  • Leukemia and Lymphoma Society of Canada
  • Cancer Research Society

Zitieren

APA

Tual, M., Bellemare-Pelletier, A., Moore, S., Guipouy, D., Farzam-Kia, N., Jafarzadeh, L., Quenneville, J., Barrette, B., Saba-El-Leil, M. K., Delisle, J. S., & Gagnon, E. (2025). MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence. Journal for ImmunoTherapy of Cancer, 13(4), e011829. https://doi.org/10.1136/jitc-2025-011829

Vancouver

Tual M, Bellemare-Pelletier A, Moore S, Guipouy D, Farzam-Kia N, Jafarzadeh L, et al. MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence. Journal for ImmunoTherapy of Cancer. 2025;13(4):e011829. doi:10.1136/jitc-2025-011829

BibTeX
@article{Tual2025,
  author = {Tual, Margaux and Bellemare-Pelletier, Angélique and Moore, Susan and Guipouy, Delphine and Farzam-Kia, Negar and Jafarzadeh, Leila and Quenneville, Jordan and Barrette, Benoit and Saba-El-Leil, Marc K and Delisle, Jean-Sebastien and Gagnon, Etienne},
  title = {MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {e011829},
  doi = {10.1136/jitc-2025-011829}
}
Kostenlos starten →